Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Two Pharma Companies Expand on the Coasts, Open New Facilities

With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.

Read More »

GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data

In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.

Read More »

AstraZeneca ties up with France’s Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement to jointly develop five cancer-killing viral immunotherapies.

Read More »

Keytruda: Mixed Results in Gastric Cancer Study

Merck & Co. reported that the checkpoint inhibitor Keytruda had mixed results as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Read More »

AACE Meeting: New Data from Phase 3 OPTIC Study

Horizon Pharma announced that new data from the Phase 3 confirmatory study evaluating teprotumumab for treating active thyroid eye disease were presented as part of a late-breaking oral presentation at the 2019 AACE Scientific and Clinical Congress.

Read More »

Gilead experimental NASH drug fails another study

Gilead Sciences Inc.’s experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study, two months after failing another clinical trial.

Read More »

IQVIA Report: Biopharma R&D Investment Increased 32 Percent Over Last 5 Years

The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.

Read More »

Teva stops testing migraine drug as cluster headache treatment

Teva Pharmaceutical Industries Ltd. will stop developing the migraine drug Ajovy for treating cluster headaches after finding the treatment was unlikely to meet the main goal of a late-stage trial.

Read More »

Lilly’s Taltz Shows Promise in Spondyloarthritis Trial

Eli Lilly announced results from the COAST-X Phase III study of Taltz in non-radiographic axial spondyloarthritis in patients who had no previous disease-modifying anti-rheumatic drug treatment.

Read More »

White House Continues to Tackle Opioid Abuse With $350 Million R&D Initiative

The White House is expanding its war on opioid addiction with a $350 million addiction research and treatment initiative.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom